All companies
Visit website
CELLMOSAIC
OperatingCellMosaic, Inc.
Healthcare · Biotech · Founded 2013
AqueaTether technologies for next-gen bioconjugates and antibody-drug conjugates
Post-money valuation ⓘ
$30.1M
As of Oct 2024 · from CellMosaic Common Stock 1 · pre-money + amount raised, not a traded price
Total raised
$54,591
Across 1 round since 2024
Latest share price
$1.47
CellMosaic Common Stock 1 offering price
Financials
FY2022–FY2024 · from SEC filings · hover any figure for its source$1.0M
$127K
2022
$816K
−$43K
2023
$961K
$27K
2024
RevenueNet income — beside revenue when positive, below the line when a loss
Metric
FY2022
FY2023
FY2024
Income statement
Revenue
$1,037,088
$815,754
$961,291
Cost of goods sold
$229,426
$212,133
$207,700
Gross margin
78%
74%
78%
Net income
$126,668
-$43,356
$27,320
Taxes paid
$0
$0
$0
Balance sheet
Cash
$311,802
$161,284
$208,495
Accounts receivable
$38,041
$11,809
$119,200
Total assets
$822,176
$537,443
$566,118
Short-term debt
$285,924
$152,682
$219,361
Long-term debt
$992,650
$882,080
$760,687
Total liabilities
$1,278,574
$1,034,762
$980,048
Other
Headcount
—
5
5
Figures as reported by the issuer in the filing shown on hover. Each year’s pill shows the assurance level of its filed statements — audited, reviewed (CPA review, less than an audit), or unaudited; no pill means the filing didn’t state one. Headcount is the filing’s point-in-time count, not a year-end average. Manually corrected figures are marked “Corrected”.
Valuation over rounds
Post-money = pre-money + amount raised · caps marked$30.1M
post-money
CellMosaic Common Stock 1
A dashed amber step is a SAFE/note valuation cap — a conversion ceiling agreed for that instrument, not a priced valuation of the company. Steps are not comparable across bases.
Fundraising history
Raised $54.6K / $1.2MInvestors 33Post-money $30.1M
Reg CF annual-report compliance
Not requiredFiled Form C-TR (terminated reporting)
Filed 1 of 2 annual reports (FY2024–FY2025)
33 investors
holder-count proxy
Reg CF issuers must file a Form C-AR each year until a Rule 202(b) termination trigger is met.
SEC filings
Source: ManualCIK 0002037196Share price $1.47
About this data. Figures are compiled from public sources — SEC EDGAR filings (Form C, C-AR, 1-A, 1-K) and funding-platform pages — and may be delayed, incomplete, or restated by the issuer. Financial statements are as reported by the issuer; each year is labeled with its assurance level (audited / reviewed / unaudited). A valuation cap is the conversion ceiling of a SAFE or convertible note, not an agreed company valuation; post-money figures are computed as pre-money plus amount raised and are not a traded price. Crowdonomics is not a broker-dealer, funding portal, or investment adviser; nothing here is investment advice or an offer to sell securities. Verify all figures against the linked EDGAR filings.